Indianapolis-based Eli Lilly announced Wednesday its COVID-19 antibody drug is showing results in reducing hospitalizations from the virus. This is the companys first data to be reported on mild to moderate cases but still needs to be reviewed by peers.

Eli Lilly says that partial results from a study testing an antibody drug give hints that it may help mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet.

Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists.

Indianapolis-based Eli Lilly is moving to Phase 3 testing of a treatment to prevent COVID-19 after initial success. The next step will be to test the drug at nursing homes where the pandemic has hit hard.

Lilly Foundation's financial commitment over five years is aimed at finding solutions to racial inequity and social injustice primarily in Indianapolis, its surrounding counties and nationally.

In phase one of the study, hospitalized COVID-19 patients are being dosed at medical facilities to closely track safety and response to the treatment, with initial results expected in about one month.

Indianapolis-based Eli Lilly and Company announced Monday that patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.

The Lilly Insulin Value Program covers most insulins made by the drug maker and is available to those with or without insurance.

The number of COVID-19 tests available in Indiana is steadily increasing, according to state health officials, but testing services remain limited to select groups of people.

Indianapolis-based Eli Lilly and Company Tuesday expanded free COVID-19 testing to first responders in addition to health care workers.